

## Special Issue

# Clinical Pharmacology and Pharmacy of Antimicrobial Agents

### Message from the Guest Editor

One of the main health threats in human and veterinary medicine today is the development of antimicrobial resistance (AMR). To successfully address the problem of AMR, it is of the highest importance to optimize the use of antimicrobials and to improve their efficacy.

Combinational usage of different antimicrobials, antimicrobials with adjuvant agents, or repositioned drugs with antimicrobial efficacy are among the possible solutions. In this Special Issue, we aim to collect studies on clinical pharmacology and pharmacy of antimicrobial agents from both human and veterinary medicine as the complex problem of AMR requires actions taken with the One Health approach, involving both fields. Studies about new or optimized usage of already authorized antimicrobials, as well as discoveries about new agents, combinations, and drug repositioning can be submitted. Pharmacodynamic, pharmacokinetic, and toxicological aspects of individual and combinational drug use can be covered. Comprehensive reviews of the field are also welcome.

### Guest Editor

Dr. Dóra Kovács

Department of Pharmacology and Toxicology, University of Veterinary Medicine Budapest, Budapest, Hungary

### Deadline for manuscript submissions

closed (30 September 2023)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/108836](https://mdpi.com/si/108836)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)